Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 12/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 12/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29399603 | 0.86 | CHRNB4 (0.50) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL22097298 | 0.79 | CHRNB4 (0.50) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL206365 | 0.76 | CHRNB4 (0.50) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL24414772 | 0.74 | CHRNB4 (0.55) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL433117 | 0.71 | CHRNB4 (0.90) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL18985115 | 0.71 | CHRNB4 (0.67) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL4967805 | 0.71 | CHRNB4 (0.57) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL15665457 | 0.70 | CHRNB4 (0.55) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL14047263 | 0.69 | CHRNB4 (0.54) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL1977761 | 0.69 | CHRNB4 (0.54) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12161731-B2 | Radioactive I-labeled larotrectinib compound and preparation method and application thereof | SHANGHAI UNIVERSITY OF MEDICINE & HEALTH SCIENCES (CN) | 2024-12-10 | — | — | US | disclosed |
| US-20220072164-A1 | RADIOACTIVE I-LABELED LAROTRECTINIB COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI UNIVERSITY OF MEDICINE&HEALTH SCIENCES (CN) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072164-A1 | RADIOACTIVE I-LABELED LAROTRECTINIB COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | IGF1R, TSHR, TRHR | CHRNB4 2453/4885CHRNA3 3061/4885ALDH1A1 3443/4885 |
| US-12161731-B2 | Radioactive I-labeled larotrectinib compound and preparation method and application thereof | IGF1R, TSHR, TRHR | CHRNB4 2453/4885CHRNA3 3061/4885ALDH1A1 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.